Nashville: Doctors at Sarah Cannon Research Institute are on the verge of a breakthrough in treating Sickle Cell Anemia. This is first of its kind because it is the first gene therapy-based treatment of the disease.
Gene editing has lead to new possibilities for treating sickle cell anemia. Advanced techniques like CRISPR allow us to edit errors at the gene level, enabling us to treat diseases like this.
This gene therapy going by the name CRISPR helps us to edit billions of cells at a single stretch, therefore, producing curable effects and saving patients from Sickle Cell Anemia. Although this therapy is on an experimental basis, the outcomes of the treatment are promising. More clinical trials on this therapy would help us to have future possibly helping to cure many diseases.
Sickle cell anemia (SCA) is a fatal condition that affects the oxygen-carrying capacity of RBCs. This disease occurs when a person inherits an abnormal chromosome 11 form either of the parents. Therefore, persons with Sickle Cell Anemia have abnormal RBCs that are defect in oxygen-carrying capacity. This results is severe pain in patients and swelling around the body. Patients with Sickle Cell Anemia usually die before their teenage years, and only 50 percent of them live after that.
This deliberating condition is of prime significance in persons involving it. In addition to this, the disease has only supportive treatment and does not provide a full cure. Therefore, this gene therapy based technique would stand as a keyhole in treating this condition.
Apply to write for us if you love writing and want to see your articles featured on Apple News, Google News, and more.